Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study
- PMID: 20593959
Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study
Abstract
Objective: To determine any association between expression of estrogen receptor (ER), progesterone receptor (PR), and Her-2/neu and clinicopathological features, including survival, of endometrial carcinoma (EMC) patients.
Methods: Samples of formalin-fixed, paraffin-embedded tissue of 108 patients with EMC treated at our institution between January 1994 and December 2007 were immunohistochemically studied.
Results: ER, PR, and Her-2/neu expression were positive in 59.3%, 65.7% and 2.8% of cases, respectively. Positive ER expression was significantly associated with grade I-II tumor while PR expression was linked with endometrioid histology, grade I-II tumor, less myometrial invasion (MI) and negative lymph node involvement. Her-2/neu expression was significantly associated with deep MI, while positive ER and negative Her-2/neu expression in combination was significantly associated with longer disease-free and overall survival.
Conclusion: ER expression is a good prognostic factor while Her-2/neu expression appears to be a poor indicator for both disease-free and overall survival, while PR tended to show favorable influence for only disease-free survival of Thai EMCs.
Similar articles
-
Expression of estrogen receptor, progesterone receptor, and Her-2/ neu in primary and extra-corporeal endometrial cancer.Histol Histopathol. 2013 Jun;28(6):787-94. doi: 10.14670/HH-28.787. Epub 2012 Dec 19. Histol Histopathol. 2013. PMID: 23255089
-
Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):553-6. Asian Pac J Cancer Prev. 2008. PMID: 19256737
-
Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer.J Obstet Gynaecol. 2018 Jan;38(1):96-102. doi: 10.1080/01443615.2017.1328591. Epub 2017 Aug 1. J Obstet Gynaecol. 2018. PMID: 28764605
-
HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature.Anticancer Res. 2005 Jul-Aug;25(4):2921-7. Anticancer Res. 2005. PMID: 16080545 Review.
-
Triple negative endometrial cancer.Ginekol Pol. 2017;88(4):212-214. doi: 10.5603/GP.a2017.0040. Ginekol Pol. 2017. PMID: 28509323 Review.
Cited by
-
Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers.Int J Mol Sci. 2022 Jan 22;23(3):1242. doi: 10.3390/ijms23031242. Int J Mol Sci. 2022. PMID: 35163166 Free PMC article. Review.
-
Immunohistochemical Expression of BCL-2 in Endometrial Carcinoma and Its Comparison With Hormone Receptor Status and Epidermal Growth Factor.Cureus. 2023 Jan 4;15(1):e33346. doi: 10.7759/cureus.33346. eCollection 2023 Jan. Cureus. 2023. PMID: 36751174 Free PMC article.
-
Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer.BMC Cancer. 2018 Jun 15;18(1):657. doi: 10.1186/s12885-018-4570-8. BMC Cancer. 2018. PMID: 29907137 Free PMC article.
-
Is the positivity of estrogen receptor or progesterone receptor different between type 1 and type 2 endometrial cancer?Oncotarget. 2017 Jan 3;8(1):506-511. doi: 10.18632/oncotarget.13471. Oncotarget. 2017. PMID: 27888807 Free PMC article.
-
Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer.PLoS One. 2018 Dec 6;13(12):e0208221. doi: 10.1371/journal.pone.0208221. eCollection 2018. PLoS One. 2018. PMID: 30521558 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous